JPWO2020205498A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020205498A5
JPWO2020205498A5 JP2021557925A JP2021557925A JPWO2020205498A5 JP WO2020205498 A5 JPWO2020205498 A5 JP WO2020205498A5 JP 2021557925 A JP2021557925 A JP 2021557925A JP 2021557925 A JP2021557925 A JP 2021557925A JP WO2020205498 A5 JPWO2020205498 A5 JP WO2020205498A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
pharmaceutically acceptable
hexenoyl
ghrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527190A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025180 external-priority patent/WO2020205498A1/fr
Publication of JP2022527190A publication Critical patent/JP2022527190A/ja
Publication of JPWO2020205498A5 publication Critical patent/JPWO2020205498A5/ja
Pending legal-status Critical Current

Links

JP2021557925A 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 Pending JP2022527190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (fr) 2019-03-29 2020-03-27 Ghrh ou ses analogues destinés à être utilisés dans le traitement d'une maladie hépatique

Publications (2)

Publication Number Publication Date
JP2022527190A JP2022527190A (ja) 2022-05-31
JPWO2020205498A5 true JPWO2020205498A5 (fr) 2023-04-05

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557925A Pending JP2022527190A (ja) 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物

Country Status (10)

Country Link
US (4) US10799562B1 (fr)
EP (1) EP3947426A4 (fr)
JP (1) JP2022527190A (fr)
KR (1) KR20210145226A (fr)
CN (1) CN113646327A (fr)
AU (1) AU2020253828A1 (fr)
CA (1) CA3133319A1 (fr)
IL (1) IL286703A (fr)
SG (1) SG11202110469PA (fr)
WO (1) WO2020205498A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (fr) 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh ou ses analogues destinés à être utilisés dans le traitement d'une maladie hépatique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009140731A (ru) * 2007-04-04 2011-05-10 Тератекнолоджиз Инк. (Ca) Фармацевтические составы, содержащие молекулы ghrh
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2015100423A2 (fr) * 2013-12-24 2015-07-02 University Of Miami Méthodes de traitement de cancer au moyen d'agonistes de ghrh
WO2017066619A1 (fr) * 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Traitement de la maladie du foie gras non alcoolique ou de la stéatohépatite non alcoolique avec de la 6-mercaptopurine à libération retardée
MX2018012716A (es) * 2016-04-19 2019-02-11 Griffon Pharmaceuticals Inc Peptidos bioactivos pegilados y usos de los mismos.
US20210059993A1 (en) * 2018-02-14 2021-03-04 Lumos Pharma, Inc. Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
WO2020205498A1 (fr) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh ou ses analogues destinés à être utilisés dans le traitement d'une maladie hépatique
CN116801788A (zh) * 2020-10-30 2023-09-22 综合医院公司 用于评估肝脏疾病的试剂盒、试剂和方法
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof

Similar Documents

Publication Publication Date Title
Negroni et al. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans
JP7491839B2 (ja) 長期作用型の変異ヒト由来線維芽細胞増殖因子の新規な用途
US20080119542A1 (en) Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
EP1369119B1 (fr) Agents de regulation d'expression d'il-12
WO2016173486A1 (fr) Utilisation de triméthazine dans la préparation de médicaments pour la prévention et le traitement de maladies hépatiques
CN107213149B (zh) 青蒿素类衍生物在制备治疗或辅助治疗自身免疫性甲状腺疾病药物中的用途
WO2023109747A1 (fr) Utilisation d'acide 2,4-dihydroxybenzoïque dans un médicament pour le traitement de maladies liées à une surcharge en fer
WO2001010387A2 (fr) Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
CN111904970B (zh) 白头翁皂苷b4在制备治疗哮喘的药物中的用途
WO2019134159A1 (fr) Préparation d'administration à la muqueuse rectale de pulsatilla chinensis (bge.) regel saponin b4 et son procédé de préparation
CN113069445A (zh) 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途
US11278542B2 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
JPWO2020205498A5 (fr)
CN109846863B (zh) 和厚朴酚的用途
Pajus et al. Erythroderma after clodronate treatment.
CN114306332B (zh) 塔拉萨敏在制备治疗关节炎药物中的应用
CN114159435B (zh) 附子灵在制备治疗关节炎药物中的应用
NL8203316A (nl) Farmaceutische preparaten met menselijk pro-insuline.
RU2785582C2 (ru) Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита
JP3014119B2 (ja) 直腸投与用赤血球造血剤
CN115501236B (zh) 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用
KR0129798B1 (ko) 간염의 예방 및 치료용 의약 조성물
Hilton Rate of the Enzymatic Breakdown of Digitoxin.
KR20050092568A (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
CN116036102A (zh) 曼那斯汀降低xelox联合治疗方案导致的肠道损伤的应用